News

Breastfeeding may lower risk of ALL


 

Breastfeeding baby

Photo by Petr Kratochvil

Breastfeeding a child may reduce his risk of developing acute lymphoblastic leukemia (ALL) but perhaps not acute myeloid leukemia (AML), according to a review published in JAMA Pediatrics.

Researchers found that breastfeeding a child for 6 months or longer was associated with a 19% lower risk of childhood leukemia, compared with no

breastfeeding or breastfeeding for a shorter period of time.

And children who were breastfed for any amount of time had an 11% lower risk of childhood leukemia than children who were never breastfed.

However, when the researchers analyzed studies of ALL and AML separately, they found that breastfeeding was not associated with a significantly lower risk of AML.

Efrat L. Amitay, PhD, and Lital Keinan-Boker, MD, PhD, of the University of Haifa in Israel, conducted this research.

In a review of 18 studies, the pair found that breastfeeding a child for 6 months or longer was associated with a significantly lower risk of childhood leukemia, compared with no breastfeeding or breastfeeding for a shorter period of time (odds ratio [OR]=0.81).

And a separate analysis of 15 studies showed that children who were breastfed for any amount of time had a lower risk of childhood leukemia than children who were never breastfed (OR=0.89).

The researchers also conducted meta-analyses of AML studies and ALL studies separately—11 ALL and 6 AML studies. And they found a significant inverse association between breastfeeding for 6 months or more and ALL risk (OR=0.82) but no significant association for AML risk (OR=0.74).

The researchers said several biological mechanisms may explain the association between breastfeeding and a reduced risk of childhood leukemia. However, more high-quality studies are needed to clarify those mechanisms.

Recommended Reading

Dexrazoxane Tx did not affect overall survival in pediatric leukemia and lymphoma
MDedge Hematology and Oncology
Less intensive childhood cancer therapy reduces late toxicities, deaths
MDedge Hematology and Oncology
David Henry's JCSO podcast, May 2015
MDedge Hematology and Oncology
DART molecule proves active against AML
MDedge Hematology and Oncology
Hodgkin lymphoma incidence on the decline worldwide
MDedge Hematology and Oncology
Herbs reduce fatigue in cancer patients
MDedge Hematology and Oncology
Team reports new method to identify immune cells
MDedge Hematology and Oncology
Improving targeted therapy for leukemia, other diseases
MDedge Hematology and Oncology
Drug improves upon standard therapy for relapsed CLL/SLL, speaker says
MDedge Hematology and Oncology
Inhibitor promotes chemosensitization in CLL
MDedge Hematology and Oncology